After investors got through the shock that Human Genome Sciences'
That's not happening quite yet.
|Benlysta Net Sales (in millions)||$7.8||$18.8||$25.7|
Source: Company releases. N/A = not applicable.
HGS broke down the sales by month, but I'm not sure what to do with the data. During the quarter, gross sales went from about $9.2 million in the first four weeks to $8.4 million to $10 million. There's improvement from the first to the third period, but the middle month shows there's still variation in the sales. Was the $10 million a trend up, or just some of that variation?
Working in HGS and marketing partner GlaxoSmithKline's
Blaming lackluster sales on holidays sounds like an excuse, but it's a necessary evil of doing quarter-over-quarter comparisons. The quarter-over-quarter growth of Dendreon's
On the other hand, there's Regeneron Pharmaceuticals
I'm not sure investors should give up on HGS just yet. Accelerated growth tends to come on without warning. But investors should keep the company on a short leash.